Comparison of pharmaceutical output value and number of enterprises in various provinces in China

New policies such as volume purchases, medical insurance negotiations, key monitoring of rational drug use, encouragement of innovation, and the revitalization of traditional Chinese medicine have had a huge impact on the pharmaceutical industry
.

Innovative drugs are rapidly emerging in Suzhou, Shanghai Zhangjiang and other places.
Traditional chemical preparation companies are receiving the baptism of consistency evaluation and centralized procurement.
The epidemic has promoted the export of epidemic prevention supplies and APIs, and traditional Chinese medicine companies are eager to cross-border or transform
.

This year is the end of the "13th Five-Year Plan" and the beginning of the "14th Five-Year Plan".
All localities are sorting out the "13th Five-Year Plan" and planning the "14th Five-Year Plan", and they are more concerned about the industry status of the province in the country.
Do a quantitative comparison
.

01 Production value

Since the founding of New China, especially the reform and opening up for more than 40 years, my country's pharmaceutical industry has achieved rapid development.
The author also published three articles to make a summary analysis "Collection! 40 years of reform and opening up, 15 pictures to understand China's pharmaceutical industry", "11 pictures to understand the 70 years since the founding of New China, great changes in medicine", "10 pictures to understand the 70 years of new China, the great achievements of traditional Chinese medicine" (all click read)
.

According to the statistics of the Research and Planning Center of the Pharmaceutical Economics News, the total output value of China's pharmaceutical industry during the "13th Five-Year Plan" period is the seven major pharmaceutical industry sub-sectors (chemical preparations, Chinese patent medicine preparations, chemical raw materials, biological products, medical equipment, hygiene materials and pharmaceutical supplies).
The compound annual growth rate of the total output value of enterprises above designated size is 7.
2%.
In 2020, the total output value of the national pharmaceutical industry will reach 4.
0 trillion yuan, an increase of 1.
3 times compared with 2016, accounting for about 4% of China's GDP
.

In 1978, the total output value of the national pharmaceutical industry was only 4.
74 billion yuan, an increase of hundreds of times
.

02 Number of companies

We have been working hard to eliminate small scattered and improve industry concentration
.

After 2016, it has increased year by year to 4,587 at the end of September 2021, 411 more than in 2016, an increase of 10%
.

The "Opinions of the State Council on Reforming the Review and Approval System for Drugs and Medical Devices" (referred to as Document No.
44) issued in August 2015 started the reform of the drug administration.
The unfinished task of improving concentration has fallen on the shoulders of consistency evaluation and volume procurement
.

On November 29, 2019, the "Notice on Several Policies and Measures for Further Deepening the Reform of the Medical and Health System with the Centralized Drug Purchase and Use as a Breakthrough" issued by the State Council Leading Group for Deepening Medical Reform stated that "to cultivate a group of large-scale enterprise groups with international competitiveness.
, to accelerate the formation of a drug production and distribution pattern with large backbone enterprises as the main body and small and medium-sized enterprises as the supplement
.

03 Ranking by Province

In terms of comparison of provinces, according to the statistics of the Pharmaceutical Economics News, Shandong and Jiangsu provinces account for the largest proportion of the total output value of the pharmaceutical industry in 2020 - both accounting for more than 15%, 15.
94% and 15.
1% respectively; ranking third.
The top five are Henan, Jilin and Guangdong, accounting for 7.
3%, 6.
7% and 6.
3% of the output value respectively.
The above five provinces together account for more than half (51.
3%) of the total output value of the national pharmaceutical industry
.

During the "Thirteenth Five-Year Plan" period, the compound annual growth rate of output value in 15 provinces exceeded 7%, and the fastest growing was Liaoning, with a compound growth rate exceeding 15%
.

What is the relationship between the total output value of the pharmaceutical industry and the number of enterprises in each province? The total output value of the pharmaceutical industry involved in this article (hereinafter referred to as "output value") refers to the total output value of the seven major pharmaceutical industry sub-sectors, but the number of enterprises only accounts for the total value of the pharmaceutical industry.
To make a simple comparison of the number of API and preparation enterprises with a large proportion of output value (hereinafter referred to as "the number of enterprises", based on the data at the end of September 2021), due to the large number of medical device enterprises (nearly 30,000), the industry is scattered and in The proportion of the total output value of the pharmaceutical industry is also not large (less than 15%)
.

Shandong Province has the largest output value, but its number of enterprises ranks third (301); Jiangsu has the largest number of enterprises (458), which ranks second in output value; and Henan, which ranks third in output value, only ranks seventh ( 202) - it can be seen that although the relationship between the output value of each province and the number of enterprises is not completely equal, the correlation is relatively large
.

The largest gap is in Heilongjiang Province, which ranks 23rd in terms of output value, but ranks 14th in terms of number of enterprises (138)
.

Some provinces have a large output value but a small number of enterprises, which may indeed be due to the large volume of a single pharmaceutical enterprise, while some provinces have a large output value but a small number of enterprises, or it may be due to the contribution of the province's medical device and hygiene industries.

The Sixth Plenary Session of the 19th Central Committee of the Communist Party of China emphasized that China's economy must achieve high-quality development, new drugs need global new drugs, and old drugs need to make up courses (consistency evaluation) are the specific practice of high-quality development in the pharmaceutical industry, and high-quality development will also promote high-quality development.

The new medical reform with volume procurement as a breakthrough is developing in depth, and the impact on the industry will also be presented in stages, and the industry pattern and the status of each province in the industry will also change accordingly